Jutatip Panaampon
Overview
Explore the profile of Jutatip Panaampon including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
27
Citations
156
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Okada S, Boonnate P, Panaampon J, Saisuwan K, Ogata-Aoki H, Abe M, et al.
Cureus
. 2024 Dec;
16(11):e74781.
PMID: 39737254
Soft tissue and bone tumors are rare, and their low frequency and diverse histological types make conducting large-scale clinical trials challenging. Patient-derived xenografts (PDX), entailing implantation of cancer specimens in...
2.
Jungcharoen P, Panaampon J, Imemkamon T, Saengboonmee C
Prog Mol Biol Transl Sci
. 2024 Oct;
209:183-214.
PMID: 39461752
Cancer immunotherapy is a revolutionised strategy that strikingly improves cancer treatment in recent years. However, like other therapeutic modalities, immunotherapy faces several challenges and limitations. Many methods have been developed...
3.
Khawkhiaw K, Chomphoo S, Kunprom W, Thithuan K, Sorin S, Yueangchantuek P, et al.
Transl Gastroenterol Hepatol
. 2024 Aug;
9:36.
PMID: 39091665
Background: Diabetes mellitus (DM) is associated with the increased risk of development and the advancement of cholangiocarcinoma (CCA). High glucose levels were previously shown for upregulating interleukin-1β (IL-1β) in CCA...
4.
Panaampon J, Sungwan P, Fujikawa S, Sampattavanich S, Jirawatnotai S, Okada S
Int Immunopharmacol
. 2024 Jul;
138:112612.
PMID: 38968862
Cholangiocarcinoma (CCA) is an aggressive and fatal cancer. The prognosis is very poor and no optimal chemotherapy has been established. Human epidermal growth factor receptor 2 (HER2, neu, and erbB2)...
5.
Panaampon J, Okada S
Explor Target Antitumor Ther
. 2024 Jul;
5(3):699-713.
PMID: 38966176
Primary effusion lymphoma (PEL) is a large B-cell neoplasm usually presenting as a serious effusion in body cavities without detectable tumor masses. It is an AIDS-related non-Hodgkin's lymphoma (HL) with...
6.
Chiawpanit C, Wathikthinnakorn M, Sawasdee N, Phanthaphol N, Sujjitjoon J, Junking M, et al.
Int Immunopharmacol
. 2024 May;
136:112273.
PMID: 38810311
Cholangiocarcinoma (CCA) presents a significant clinical challenge which is often identified in advanced stages, therby restricting the effectiveness of surgical interventions for most patients. The high incidence of cancer recurrence...
7.
Khawkhiaw K, Panaampon J, Imemkamon T, Saengboonmee C
World J Gastrointest Oncol
. 2024 May;
16(5):1676-1682.
PMID: 38764841
Gastrointestinal (GI) cancer is a malignancy arising in the digestive system and accounts for approximately a third of increasing global cancer-related mortality, especially in the colorectum, esophagus, stomach, and liver....
8.
Sungwan P, Panaampon J, Kariya R, Kamio S, Nakagawa R, Hirozane T, et al.
Hum Cell
. 2024 May;
37(4):1215-1225.
PMID: 38755432
TK-ALCL1, a novel anaplastic lymphoma kinase (ALK)-positive anaplastic large-cell lymphoma (ALK ALCL) cell line, was established from the primary tumor site of a 59-year-old Japanese male patient. The immune profile...
9.
Jungcharoen P, Thivakorakot K, Thientanukij N, Kosachunhanun N, Vichapattana C, Panaampon J, et al.
Explor Target Antitumor Ther
. 2024 May;
5(2):316-331.
PMID: 38745773
Cancer immunotherapy has emerged as a groundbreaking field, offering promising and transformative tools for oncological research and treatment. However, it faces several limitations, including variations in cancer types, dependence on...
10.
Panaampon J, Zhou Y, Saengboonmee C
Int Immunopharmacol
. 2023 Jun;
121:110528.
PMID: 37364322
Metformin, a biguanide antidiabetic, has been studied for its repurposing effects in oncology. Although a modest effect was observed in a single-agent regimen, metformin can synergize the anti-tumor effects of...